Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management

Abstract

5-HT3 antagonists have been available as oral and intravenous preparations for decades. The availability more recently of transdermal granisetron and the anticipated availability of a subcutaneous granisetron preparation have provided helpful alternatives to patients, and these preparations have been shown to have less potential to prolong QT than other drugs in the class. © 2013 Mason and Moon, publisher and licensee Dove Medical Press Ltd.